Combination of targeted multikinase inhibitor and radioiodine: a new strategy of treatment for advanced differentiated thyroid carcinoma

Abstract

Advanced differentiated thyroid carcinoma (ADTC) lacks effective treatment options, and has a poor prognosis, which is an urgent clinical problem to be resolved. Targeted multikinase inhibitor(MKI) has been approved for the treatment of radioiodine refractory differentiated thyroid carcinoma, and have recently been recommended as a preoperative neoadjuvant therapy agents for locally ADTC. Although radioiodine therapy is the standard postoperative treatment for ADTC, it has certain limitations. MKI combined with radioiodine therapy is expected to become a new strategy of treatment for ADTC.

Keywords

• |advanced differentiated thyroid carcinoma|multikinase inhibitor|radioiodine|131i